Efficacy and safety of reproxalap for the treatment of dry eye disease: a systematic review and meta-analysis
Annals of Middle Eastern Medicine · 24.10.2026 · 2 (5) · 652-663
DOI: 10.24911/amem.15-3085 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Annals of Middle Eastern Medicine, online erschienen am 24.10.2026. Verfasst von Osama Almajhadi und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Reproxalap, a reactive aldehyde species inhibitor, has been proposed for dry eye disease (DED), but trial findings are inconsistent, and no quantitative synthesis exists. We assessed the efficacy and safety of reproxalap 0.25% ophthalmic solution versus vehicle in adults with DED.
Methods
PubMed, Web of Science, ClinicalTrials.gov, gray literature, and manufacturer sources were searched through June 2025 (International Prospective Register of Systematic Reviews CRD420251069765; Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020). Two reviewers independently screened, extracted data, and assessed risk of bias. Random- or fixed-effects models were used according to heterogeneity. Standardized mean differences (SMDs), mean differences (MDs), and risk ratios (RRs) were pooled with 95% confidence intervals (CIs). Certainty was assessed using Grading of Recommendations, Assessment, Development, and Evaluations.
Results
Eight randomized controlled trials (1,436 participants) were included. Reproxalap did not significantly improve ocular dryness (SMD, −0.07; 95% CI, −0.24 to 0.10; I² = 47%; p = 0.43) or conjunctival redness (MD, −0.06; 95% CI, −0.19 to 0.07; I² = 73%; p = 0.36; random-effects). Tear production significantly increased (MD, 2.20 mm; 95% CI, 1.45-2.94; I² = 0%; p < 0.0001). Adverse events (AEs) were more frequent with reproxalap (overall RR, 16.30; 95% CI, 4.46-59.55; I² = 94%; p < 0.0001), although the magnitude of excess varied by study setting: chamber trials showed a larger effect (RR, 25.98; 95% CI, 15.17-44.48; I² = 0%), while field trials showed a smaller but still elevated risk (RR, 6.01; 95% CI, 1.25-28.85). Certainty was moderate for AEs and tear production, and very low for dryness and redness.
Conclusion
Reproxalap 0.25% significantly increased tear production by 2.2 mm, although its clinical relevance is uncertain given the ≥10 mm responder threshold. No benefit was observed for ocular dryness or conjunctival redness. Larger, well-designed field trials are needed to confirm clinical benefit.
Zitieren
APA
Almajhadi, O., Alharthi, R., Althobaiti, G., Alharbi, E., & Qurashi, M. A. (2026). Efficacy and safety of reproxalap for the treatment of dry eye disease: a systematic review and meta-analysis. Annals of Middle Eastern Medicine, 2(5), 652-663. https://doi.org/10.24911/amem.15-3085
Vancouver
Almajhadi O, Alharthi R, Althobaiti G, Alharbi E, Qurashi MA. Efficacy and safety of reproxalap for the treatment of dry eye disease: a systematic review and meta-analysis. Annals of Middle Eastern Medicine. 2026;2(5):652-663. doi:10.24911/amem.15-3085
BibTeX
@article{Almajhadi2026,
author = {Almajhadi, Osama and Alharthi, Rana and Althobaiti, Ghadi and Alharbi, Elham and Qurashi, Majed Al},
title = {Efficacy and safety of reproxalap for the treatment of dry eye disease: a systematic review and meta-analysis},
journal = {Annals of Middle Eastern Medicine},
year = {2026},
volume = {2},
number = {5},
pages = {652--663},
doi = {10.24911/amem.15-3085}
}
EUVIMED